Antinociceptive effect and GC/MS analysis of Rosmarinus officinalis L. essential oil from its aerial parts.
The rationale of this investigation was to examine the antinociceptive properties of the essential oil obtained from Rosmarinus officinalis aerial parts, using a rat model of arthritic pain. The essential oil (100, 300 and 600 mg/kg, I. P.) produced a dose-dependent antinociceptive effect, manifested as a significant reduction in the dysfunction in the pain-induced functional impairment model in the rat (PIFIR model), mainly at high doses. Chemical constituents of the essential oil were further analyzed by gas chromatography-mass spectrometry (GC/MS). The major compounds in the essential oil were alpha-pinene (14.10 %), camphene (11.47 %), beta-pinene (12.02 %), myrcene (3.31 %), alpha-phellandrene (7.87 %), eucalyptol (8.58 %), 2-bornanone (3.42 %), camphor (8.75 %), isoborneol (3.48 %), borneol (4.85 %) and borneol acetate (6.49 %). The antinociceptive effects of R. officinalis essential oil were tested in combination with 0.12 mg/kg WAY100635, s. c. (an antagonist of 5-HT(1A) receptors) or 1 mg/kg naloxone, i. p. (an antagonist of endogenous opioids receptors), demonstrating in both cases an inhibition of the antinociceptive response. This study suggests an involvement, at least in part, of the serotonergic system via 5-HT(1A) receptors and endogenous opioids in the antinociceptive effect of R. officinalis essential oil in the PIFIR model.
Martínez
Ana L
AL
Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, México, D. F., México.
González-Trujano
Maria Eva
ME
Pellicer
Francisco
F
López-Muñoz
Francisco J
FJ
Navarrete
Andrés
A
D000700:Analgesics / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D001168:Arthritis / Q000139:chemically induced / Q000188:drug therapy*; D002849:Chromatography, Gas; D008297:Male; D013058:Mass Spectrometry; D009270:Naloxone / Q000494:pharmacology; D009292:Narcotic Antagonists / Q000494:pharmacology; D009822:Oils, Volatile / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D010146:Pain / Q000139:chemically induced / Q000188:drug therapy*; D010879:Piperazines / Q000494:pharmacology; D035261:Plant Components, Aerial; D010936:Plant Extracts / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D011725:Pyridines / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D027542:Rosmarinus / Q000737:chemistry*; D012702:Serotonin Antagonists / Q000494:pharmacology; D013729:Terpenes / Q000302:isolation & purification*; D014527:Uric Acid / Q000009:adverse effects
D000700:Analgesics; D009292:Narcotic Antagonists; D009822:Oils, Volatile; D010879:Piperazines; D010936:Plant Extracts; D011725:Pyridines; D012702:Serotonin Antagonists; D013729:Terpenes; D014527:Uric Acid; D009270:Naloxone; C090413:N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide